ApoA-I-Directed Therapies for the Management of Atherosclerosis.
Several recent reports have raised doubts about the atheroprotective role of high-density lipoprotein cholesterol (HDL-C). Nevertheless, a substantial body of work supports the validity of pharmacological interventions able to enhance HDL function, as opposed to raising HDL-C levels per se. In this article, we briefly review the development of pharmacological interventions that target apoA-I and HDL function as a means of reducing atherosclerotic risk: small molecule pharmaceuticals, small HDL mimetic peptides, and infusion of apoA-I-containing particles.
Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Room 11-132, Philadelphia, PA, 19104, USA, jsmillar@upenn.edu.
John S
JS
Millar
Marina
M
Cuchel
D000818:Animals; D016632:Apolipoprotein A-I / Q000037:antagonists & inhibitors*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D040761:Biomimetic Materials / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000037:antagonists & inhibitors; D006801:Humans; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism
C505693:APOA1 protein, human; D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D047492:Peroxisome Proliferator-Activated Receptors